STAG2 and cancer: Alternate transcriptional and developmental consequences with Stag2 and Rad21 deficiency have implications for the amelioration of cohesinopathies; Wnt agonists have been explored as potential therapeutic agents for individuals with CdLS (Grazioli et al., 2021), and, additionally, for the treatment of cohesin-mutant cancers (Chin et al., 2020).